A bottle of Fetzima. Depression The FDA approved<unk>  for the treatment of major depressive disorder based on the results of one 10-week phase II and four 8-week phase III clinical trials. Four of the five trials demonstrated a statistically significant superiority to placebo as measured by the Montgomery–Åsberg Depression Rating Scale. Superiority to placebo was also demonstrated by improvement in the Sheehan Disability Scale.
Levomilnacipran
Ciltacabtagene autoleucel
Brexucabtagene autoleucel
Lisocabtagene maraleucel
Milnacipran
Pivhydrazine
Darvadstrocel
Damoctocog alfa pegol